Tazim Dowlut-McElroy1, Stephanie Shin2, Elizabeth Stepanek3, David Jacobsohn4, Veronica Gomez-Lobo5. 1. Pediatric and Adolescent Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, United States; Department of Surgery, Children's National Hospital, Washington, DC, United States. Electronic address: tazim.dowlut-mcelroy@nih.gov. 2. Georgetown University School of Medicine, Washington, DC, United States. 3. Division of Hematology, Children's National Hospital, Washington DC, United States. 4. Division of Blood and Marrow Transplantation, Children's National Hospital, Washington DC, United States. 5. Pediatric and Adolescent Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, United States; Department of Surgery, Children's National Hospital, Washington, DC, United States.
Abstract
STUDY OBJECTIVE: To assess genital symptomatology, characterize the findings of genital examination, and describe the incidence and treatment of vulvovaginal graft-versus-host disease (vvGvHD) in girls and adolescents after allogeneic hematopoietic stem cell transplantation (HSCT). DESIGN: Retrospective cohort. SETTING: Metropolitan-area children's hospital. PARTICIPANTS: Female allogeneic HSCT recipients ages 0 to 22 years. MAIN OUTCOME MEASURES: Genital symptoms, genital examination, diagnosis, and treatment of vvGvHD. RESULTS: A total of 57 participants were included in the analysis. The median age at the time of HSCT was 10 years (range 4 months-23 years). Most (n = 40, 71%) underwent transplant for a nonmalignant condition, most commonly sickle cell anemia (n = 19, 33%). The median time of onset of GvHD post HSCT was 62 days (IQR = 42 to 151 days). The most common initial site of GvHD was skin (n = 21, 64%), followed by GI tract (n = 10, 30%). Three patients (5%) were diagnosed with vvGvHD. The time of onset of vvGvHD post HSCT ranged from 62 to 1565 days. One patient (33%) was asymptomatic at the time of diagnosis. There was no difference in diagnosis of vvGvHD when race (P = 0.15), age at allogeneic HSCT (P = 0.64), nonmalignant vs malignant indication (P = 0.21), source of stem cells (P = 0.25), partial vs full human leukocyte antigens (HLA) donor match (P = 0.34), and GvHD prophylaxis regimen (P = 0.18) were compared. None had isolated vvGvHD. Vulvovaginal GvHD was preceded by skin GvHD in 1 patient, was preceded by lung GvHD in 1 patient, and occurred concurrently with skin GvHD in the third patient. CONCLUSIONS: Pediatric vvGvHD can occur within the first 100 days after transplant and can be asymptomatic. Routine gynecologic evaluation post allogeneic HSCT in children and adolescents should include a thorough review of vulvovaginal symptoms and a gynecologic exam for the detection and treatment of vvGvHD.
STUDY OBJECTIVE: To assess genital symptomatology, characterize the findings of genital examination, and describe the incidence and treatment of vulvovaginal graft-versus-host disease (vvGvHD) in girls and adolescents after allogeneic hematopoietic stem cell transplantation (HSCT). DESIGN: Retrospective cohort. SETTING: Metropolitan-area children's hospital. PARTICIPANTS: Female allogeneic HSCT recipients ages 0 to 22 years. MAIN OUTCOME MEASURES: Genital symptoms, genital examination, diagnosis, and treatment of vvGvHD. RESULTS: A total of 57 participants were included in the analysis. The median age at the time of HSCT was 10 years (range 4 months-23 years). Most (n = 40, 71%) underwent transplant for a nonmalignant condition, most commonly sickle cell anemia (n = 19, 33%). The median time of onset of GvHD post HSCT was 62 days (IQR = 42 to 151 days). The most common initial site of GvHD was skin (n = 21, 64%), followed by GI tract (n = 10, 30%). Three patients (5%) were diagnosed with vvGvHD. The time of onset of vvGvHD post HSCT ranged from 62 to 1565 days. One patient (33%) was asymptomatic at the time of diagnosis. There was no difference in diagnosis of vvGvHD when race (P = 0.15), age at allogeneic HSCT (P = 0.64), nonmalignant vs malignant indication (P = 0.21), source of stem cells (P = 0.25), partial vs full human leukocyte antigens (HLA) donor match (P = 0.34), and GvHD prophylaxis regimen (P = 0.18) were compared. None had isolated vvGvHD. Vulvovaginal GvHD was preceded by skin GvHD in 1 patient, was preceded by lung GvHD in 1 patient, and occurred concurrently with skin GvHD in the third patient. CONCLUSIONS: Pediatric vvGvHD can occur within the first 100 days after transplant and can be asymptomatic. Routine gynecologic evaluation post allogeneic HSCT in children and adolescents should include a thorough review of vulvovaginal symptoms and a gynecologic exam for the detection and treatment of vvGvHD.
Authors: Simonetta Spinelli; Sandra Chiodi; Sergio Costantini; Maria Teresa Van Lint; Anna Maria Raiola; Gian Battista Ravera; Andrea Bacigalupo Journal: Haematologica Date: 2003-10 Impact factor: 9.941
Authors: M A Schubert; K M Sullivan; M M Schubert; J Nims; M Hansen; J E Sanders; J O'Quigley; R P Witherspoon; C D Buckner; R Storb Journal: Bone Marrow Transplant Date: 1990-06 Impact factor: 5.483
Authors: Mukta Arora; Corey S Cutler; Madan H Jagasia; Joseph Pidala; Xiaoyu Chai; Paul J Martin; Mary E D Flowers; Yoshihiro Inamoto; George L Chen; William A Wood; Nandita Khera; Jeanne Palmer; Hien Duong; Sally Arai; Sebastian Mayer; Iskra Pusic; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2015-11-02 Impact factor: 5.742
Authors: Stephanie M Allen; Cynthia S Liang; Arina E Chesnokova; Krista J Childress; Kristin F Pascoe; Jennifer E Dietrich Journal: J Pediatr Adolesc Gynecol Date: 2020-08-08 Impact factor: 1.814